Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

Scherlinger, Marc; Germain, Vincent; Labadie, Céline; Barnetche, Thomas; Truchetet, Marie-Élise; Bannwarth, B; Mehsen‐Cetre, Nadia; Richez, Christophe; Schaeverbeke, Thierry; Acronim, Fhu

doi:10.1016/j.jbspin.2017.10.003

Cited by 70 publications

(86 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study demonstrates a high baseline patient acceptance of biosimilar concept despite being initially unfamiliar and highlights the impact of patients' trust in their rheumatologist. Our findings are comparable to other international studies, with 70% acceptance rate reported in Germany and 89% in France when biosimilars were introduced. We found that the patients likely to refuse biosimilars tended to be older and more likely to refuse generic medicines, mirroring the findings of the French cohort .…”

Section: Discussionsupporting

confidence: 90%

“…Our findings are comparable to other international studies, with 70% acceptance rate reported in Germany and 89% in France when biosimilars were introduced. We found that the patients likely to refuse biosimilars tended to be older and more likely to refuse generic medicines, mirroring the findings of the French cohort . It could be particularly valuable to provide these patients with reassuring and positive framing about biosimilars, as this has been demonstrated to increase patient acceptance of these medicines and to reduce the nocebo effect .…”

Section: Discussionsupporting

confidence: 90%

“…We found that the patients likely to refuse biosimilars tended to be older and more likely to refuse generic medicines, mirroring the findings of the French cohort. 5 It could be particularly valuable to provide these patients with reassuring and positive framing about biosimilars, as this has been demonstrated to increase patient acceptance of these medicines and to reduce the nocebo effect. 9,10 Although there are distinct differences between generics and biosimilars, it is likely that some patients extrapolate their negative perception of generic medicines to the biosimilar.…”

Section: Discussionmentioning

confidence: 99%

“…Although the predominant focus of current literature has been on physicians' awareness and confidence of biosimilars, an effective introduction of biosimilars requires an understanding of patient attitudes of these medicines. Incomplete patient acceptance was identified as one of the leading factors limiting the switch from bio‐originator to its biosimilar in European rheumatology cohorts …”

Section: Study Cohort Characteristicsmentioning

confidence: 99%

“…Incomplete patient acceptance was identified as one of the leading factors limiting the switch from bio-originator to its biosimilar in European rheumatology cohorts. 4,5 Our study was undertaken during the 2017 period when etanercept biosimilar (SB4) became the first biosimilar medicine for RA in Australia to be listed on the Pharmaceutical Benefits Scheme for dispensing through community pharmacies. 6 Importantly this study was undertaken several months prior to any significant prescribing of biosimilars precisely in order to understand baseline attitudes.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis

Kovitwanichkanont

Raghunath

Wang

et al. 2020

Internal Medicine Journal

View full text Add to dashboard Cite

Biosimilars are increasingly adopted to improve affordability of biologics. An effective introduction of biosimilars requires an understanding of patient acceptance of these agents. We performed a cross‐sectional study of 132 patients with rheumatoid arthritis prior to the introduction of biosimilar switching or prescribing in this cohort. Despite being unfamiliar with biosimilars, most patients are willing to accept biosimilar medicines if recommended by their rheumatologist. Patient concerns about biosimilar uptake mainly focus on concerns about its efficacy. There is a significant correlation between patient attitudes towards biosimilar and generic medicines.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Study Cohort Characteristicsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis

Kovitwanichkanont

Raghunath

Wang

et al. 2020

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

Barbier

Ebbers

Declerck

et al. 2020

Clin Pharma and Therapeutics

111

102

View full text Add to dashboard Cite

To date, no consensus exists among stakeholders about switching patients between reference biological products (RPs) and biosimilars, which may have been curbing the implementation of biosimilars in clinical practice. This study synthesizes the available data on switching and assesses whether switching patients from a RP to its biosimilar or vice versa affects efficacy, safety, or immunogenicity outcomes. A total of 178 studies, in which switch outcomes from a RP to a biosimilar were reported, was identified. Data were derived from both randomized controlled trials and real‐world evidence. Despite the limitations stemming from a lack of a robust design for most of the studies, the available switching data do not indicate that switching from a RP to a biosimilar is associated with any major efficacy, safety, or immunogenicity issues. Some open‐label and observational studies reported increased discontinuation rates after switching, which were mainly attributed to nocebo effects. Involvement of the prescriber in any decision to switch should remain and attention should be paid to the mitigation of a potential nocebo effect.

show abstract

Doctor’s aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center

Tabaa

Etcheto

Dumas

et al. 2020

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance

Cited by 70 publications

References 19 publications

Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis

Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

Doctor’s aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center

Contact Info

Product

Resources

About